User banner image
User avatar
  • admin

Posts

Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors

A 2026 industry overview of the Direct Meds telehealth platform, including its compounded GLP-1 medication access model, pricing structure, delivery formats, consultation process, pharmacy sourcing,...

A Parent’s Guide to Navigating Picky Eating with Confidence

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — (Feature Impact) For families with young children, mealtimes can often feel like negotiations or even battles. If...

BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments

The Hydrafacial Treatment and SkinStylus Nano-Channeling Protocol Addresses Rising Consumer Demand for Combination Treatments That Can Improve Performance and Enhance Results LONG BEACH, Calif., March...

Trex Introduces Fire-Resistant Outdoor Decking

New Trex® Refuge™ Decking is Engineered to Resist Fire Ignition and Slow Flame Spread WINCHESTER, Va., March 09, 2026 (GLOBE NEWSWIRE) — In areas prone...

Lulus to Report Fourth Quarter and Full Year 2025 Results on March 30, 2026

CHICO, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU), the women’s clothing brand offering modern,...

United States Hair Wigs And Extensions Market Forecast Report 2025-2033: Custom-fit and 3D-created Wigs That Meet Personal Tastes are Also Becoming Popular, Aided by Digital Fitting and VR

The U.S. Hair Wigs and Extensions Market is projected to rise significantly from $2.35 billion in 2025 to $3.99 billion by 2033, marking a robust...

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer 

Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel Smital Shah appointed Chief Financial...

Route 92 Medical Enrolls First Patient in SUMMIT RISE Study

SUMMIT RISE is expected to enroll up to 500 patients to evaluate the performance of Route 92 Medical’s neurovascular intervention device portfolio WEST JORDAN, Utah,...

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA...